Dyne Therapeutics, Inc. DYN DYNE-251DM1 — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dyne Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dyne Therapeutics, Inc.'s dyne-251dm1 — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dyne Therapeutics, Inc.'s DYNE-251DM1 — research and development expense?
- Dyne Therapeutics, Inc. (DYN) reported DYNE-251DM1 — research and development expense of $37.75M in Q1 2026.
- How has Dyne Therapeutics, Inc.'s DYNE-251DM1 — research and development expense changed year-over-year?
- Dyne Therapeutics, Inc.'s DYNE-251DM1 — research and development expense increased by 79.0% year-over-year, from $21.09M to $37.75M.
- What is the long-term trend for Dyne Therapeutics, Inc.'s DYNE-251DM1 — research and development expense?
- Over 3 years (2022 to 2025), Dyne Therapeutics, Inc.'s DYNE-251DM1 — research and development expense has grown at a 26.9% compound annual growth rate (CAGR), from $48.39M to $98.93M.
- What does DYNE-251DM1 — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of a specific therapeutic candidate. It captures the investment required to progress the asset through preclinical studies and clinical trials, including personnel, laboratory, and third-party contract costs. Monitoring this expense provides insight into the capital intensity and development velocity of the company's pipeline assets.